Logo (pure-white background + navy borde
  • YouTube
  • Facebook
  • Twitter
  • Instagram

© 2020 Diverse Health Hub, LLC

  • Diverse Health Hub Team

Disparities in treatment patterns and outcomes among patients with multiple myeloma

Updated: Nov 16, 2019

Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances. The study found that on average it took about three months for white patients to start novel therapy after diagnosis, while for both African Americans and Hispanics it took about five months.  

The time between diagnosis and treatment is crucial to multiple myeloma outcomes. If treatment is delayed, multiple myeloma patients can suffer organ damage, kidney dysfunction, anemia, skeletal fractures, infections, and other serious conditions. Best practice is to start patients on immunomodulatory drugs such as lenalidomide and/or proteasome inhibitors such as bortezomib and carfilzomib. The use of these therapies has more than doubled survival of multiple myeloma patients within the past decade.